How treating a virus in HIV patients may lower heart disease risk
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
This study is looking at whether treating a common virus called cytomegalovirus (CMV) can help improve heart health for people living with HIV who are on medication, and it involves testing a new antiviral drug to see if it can reduce inflammation and lower the risk of heart problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10891816 on NIH RePORTER |
What this research studies
This research investigates the role of asymptomatic cytomegalovirus (CMV) replication in increasing cardiovascular risk among people living with HIV who are on antiretroviral therapy. The study aims to determine if treating this viral replication can reduce inflammation and improve heart health in these patients. By utilizing a clinical trial that tests a new antiviral drug, letermovir, the research will assess changes in vascular inflammation and endothelial function. Participants will be monitored for cardiovascular health indicators to evaluate the effectiveness of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are on antiretroviral therapy and have asymptomatic CMV replication.
Not a fit: Patients who are not living with HIV or those who do not have asymptomatic CMV replication may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cardiovascular health and reduced heart disease risk for HIV patients.
How similar studies have performed: Previous studies have shown that treating asymptomatic CMV replication can reduce inflammatory markers in HIV patients, suggesting potential success for this approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Hunt, Peter W — University of California, San Francisco
- Study coordinator: Hunt, Peter W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.